SEC Form 4 · accession 0001209191-15-044973
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian Tambi
Director
Period of report
May 19, 2015
Accepted (ET)
May 20, 2015 · 5:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 19, 2015 | M | 1,200 | $1.22 | A | 1,200 | D | |
| Common StockF1 | May 19, 2015 | S | 1,200 | $60.01 | D | 0 | D | |
| Common Stock | May 20, 2015 | M | 3,900 | $1.22 | A | 3,900 | D | |
| Common StockF2 | May 20, 2015 | S | 3,900 | $60.14 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5,F3,F4 | $1.22 | May 19, 2015 | M | 1,200 | D | — | Feb 21, 2020 | Common Stock | 1,200 | 25,627 | D |
| Stock Option (right to buy)F4 | $1.22 | May 20, 2015 | M | 3,900 | D | — | Feb 21, 2020 | Common Stock | 3,900 | 21,727 | D |
Explanation of responses
- F1The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.04 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.59 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The exercise price reflects a 3-for-2 stock split effected by the Issuer on March 28, 2014
- F4The option is fully vested and exercisable.
- F5On March 28, 2014, the Issuer effected a 3-for-2 stock split, resulting in the reporting person's ownership of 8,942 additional options.